Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

Plasma levels of C-type lectin REG3α and gut damage in people with HIV.

Isnard S, Ramendra R, Dupuy FP, Lin J, Fombuena B, Kokinov N, Kema I, Jenabian MA, Lebouché B, Costiniuk CT, Ancuta P, Bernard NF, Silverman MS, Lakatos PL, Durand M, Tremblay C, Routy JP; Montreal primary HIV infection study; Canadian cohort of HIV+ slow progressors; Canadian HIV and Aging cohort groups.

J Infect Dis. 2019 Aug 23. pii: jiz423. doi: 10.1093/infdis/jiz423. [Epub ahead of print]

PMID:
31504638
2.

Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease.

Morou A, Brunet-Ratnasingham E, Dubé M, Charlebois R, Mercier E, Darko S, Brassard N, Nganou-Makamdop K, Arumugam S, Gendron-Lepage G, Yang L, Niessl J, Baxter AE, Billingsley JM, Rajakumar PA, Lefebvre F, Johnson RP, Tremblay C, Routy JP, Wyatt RT, Finzi A, Douek DC, Kaufmann DE.

Nat Immunol. 2019 Aug;20(8):1059-1070. doi: 10.1038/s41590-019-0418-x. Epub 2019 Jul 15.

PMID:
31308541
3.
4.

HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy.

Miller RL, Ponte R, Jones BR, Kinloch NN, Omondi FH, Jenabian MA, Dupuy FP, Fromentin R, Brassard P, Mehraj V, Chomont N, Poon AFY, Joy JB, Brumme ZL, Routy JP; ORCHID Study Group.

J Virol. 2019 Aug 13;93(17). pii: e00755-19. doi: 10.1128/JVI.00755-19. Print 2019 Sep 1.

PMID:
31189714
5.

The anti-inflammatory IL-37/SIGIRR axis is functionally compromised in HIV infection.

Samarani S, Abulkhir A, Amre D, Mehraj V, Tremblay C, Routy JP, Ahmad A.

AIDS. 2019 Sep 1;33(11):1693-1703. doi: 10.1097/QAD.0000000000002271.

PMID:
31149943
6.

Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals.

Kant S, Zhang N, Routy JP, Tremblay C, Thomas R, Szabo J, Côté P, Trottier B, LeBlanc R, Rouleau D, Harris M, Dupuy FP, Bernard NF.

Viruses. 2019 May 28;11(6). pii: E487. doi: 10.3390/v11060487.

7.

Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol.

Routy JP, Isnard S, Mehraj V, Ostrowski M, Chomont N, Ancuta P, Ponte R, Planas D, Dupuy FP, Angel JB; Lilac Study Group.

BMJ Open. 2019 Apr 20;9(4):e028444. doi: 10.1136/bmjopen-2018-028444.

8.

Circulating LPS and (1→3)-β-D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation.

Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, Routy JP.

Front Immunol. 2019 Mar 18;10:465. doi: 10.3389/fimmu.2019.00465. eCollection 2019. Review.

9.

Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets.

Monette A, Morou A, Al-Banna NA, Rousseau L, Lattouf JB, Rahmati S, Tokar T, Routy JP, Cailhier JF, Kaufmann DE, Jurisica I, Lapointe R.

J Clin Invest. 2019 Mar 26;129(6):2463-2479. doi: 10.1172/JCI125301.

10.

Following the elite: Targeting immunometabolism to limit HIV pathogenesis.

Routy JP, Isnard S, Ramendra R.

EBioMedicine. 2019 Apr;42:8-9. doi: 10.1016/j.ebiom.2019.03.053. Epub 2019 Mar 22. No abstract available.

11.

Human T-cell lymphotropic virus 1/2 and human immunodeficiency virus antibodies identification among transactional sex workers and drug users in the Dominican Republic.

Paulino-Ramirez R, Tapia L, Ruiz-Matuk C, Charow R, Budhwani H, Routy JP.

Trans R Soc Trop Med Hyg. 2019 Jun 1;113(6):293-297. doi: 10.1093/trstmh/trz012.

PMID:
30892643
12.

Circulating (1→3)-β-D-Glucan is associated with immune activation during HIV infection.

Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, Kema I, Jenabian MA, Costiniuk C, Lebouché B, Thomas R, Coté P, Leblanc R, Baril JG, Durand M, Chartrand-Lefebvre C, Tremblay C, Ancuta P, Bernard NF, Sheppard DC, Routy JP; Montreal Primary HIV-infection Study and Canadian HIV and Aging Cohort Study Groups.

Clin Infect Dis. 2019 Mar 16. pii: ciz212. doi: 10.1093/cid/ciz212. [Epub ahead of print]

PMID:
30877304
13.

The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study.

Luo L, Wang N, Yue Y, Han Y, Lv W, Liu Z, Qiu Z, Lu H, Tang X, Zhang T, Zhao M, He Y, Shenghua H, Wang M, Li Y, Huang S, Li Y, Liu J, Tuofu Z, Routy JP, Li T.

BMC Infect Dis. 2019 Mar 14;19(1):257. doi: 10.1186/s12879-019-3847-0.

14.

HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy.

Cattin A, Wiche Salinas TR, Gosselin A, Planas D, Shacklett B, Cohen EA, Ghali MP, Routy JP, Ancuta P.

AIDS. 2019 Jul 1;33(8):1293-1306. doi: 10.1097/QAD.0000000000002195.

PMID:
30870200
15.

CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection.

Mehraj V, Ramendra R, Isnard S, Dupuy FP, Lebouché B, Costiniuk C, Thomas R, Szabo J, Baril JG, Trottier B, Coté P, LeBlanc R, Durand M, Chartrand-Lefebvre C, Kema I, Zhang Y, Finkelman M, Tremblay C, Routy JP.

Front Immunol. 2019 Feb 21;10:289. doi: 10.3389/fimmu.2019.00289. eCollection 2019.

16.

Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?

Moreno S, Perno CF, Mallon PW, Behrens G, Corbeau P, Routy JP, Darcis G.

HIV Med. 2019 Apr;20 Suppl 4:2-12. doi: 10.1111/hiv.12716. Review.

PMID:
30821898
17.

Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection.

Pardons M, Baxter AE, Massanella M, Pagliuzza A, Fromentin R, Dufour C, Leyre L, Routy JP, Kaufmann DE, Chomont N.

PLoS Pathog. 2019 Feb 27;15(2):e1007619. doi: 10.1371/journal.ppat.1007619. eCollection 2019 Feb.

18.

Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles.

Tumiotto C, Alves BM, Recordon-Pinson P, Jourdain M, Bellecave P, Guidicelli GL, Visentin J, Bonnet F, Hessamfar M, Neau D, Sanchez J, Brander C, Sajadi M, Eyzaguirre L, Soares EA, Routy JP, Soares MA, Fleury H.

PLoS One. 2019 Feb 27;14(2):e0212347. doi: 10.1371/journal.pone.0212347. eCollection 2019.

19.

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.

Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N.

Nat Commun. 2019 Feb 18;10(1):814. doi: 10.1038/s41467-019-08798-7.

20.

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.

Costiniuk CT, Saneei Z, Routy JP, Margolese S, Mandarino E, Singer J, Lebouché B, Cox J, Szabo J, Brouillette MJ, Klein MB, Chomont N, Jenabian MA.

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

21.

Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross-sectional study.

Costiniuk CT, Nitulescu R, Saneei Z, Wasef N, Salahuddin S, Wasef D, Young J, de Castro C, Routy JP, Lebouché B, Cox J, Smith BM, Ambroise S, Pexos C, Patel M, Szabo J, Haraoui LP, de Pokomandy A, Tsoukas C, Falutz J, LeBlanc R, Giannakis A, Frenette C, Jenabian MA, Bourbeau J, Klein MB.

HIV Med. 2019 Mar;20(3):192-201. doi: 10.1111/hiv.12699. Epub 2019 Jan 8.

22.

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Chen J, Mehraj V, Szabo J, Routy B, Michel RP, Routy JP.

Curr Oncol. 2018 Dec;25(6):e592-e596. doi: 10.3747/co.25.4119. Epub 2018 Dec 1.

23.

New Th17-specific therapeutic strategies for HIV remission.

Planas D, Routy JP, Ancuta P.

Curr Opin HIV AIDS. 2019 Mar;14(2):85-92. doi: 10.1097/COH.0000000000000522.

PMID:
30543544
24.

Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands.

Psomas CK, Fidler S, Macartney M, Jeffreys R, Reilly L, Collins S, Moreno S, Routy JP, Pasternak A, Kinloch-de Loës S.

J Virus Erad. 2018 Oct 1;4(4):238-247.

25.

CD16+ monocytes give rise to CD103+RALDH2+TCF4+ dendritic cells with unique transcriptional and immunological features.

Wacleche VS, Cattin A, Goulet JP, Gauchat D, Gosselin A, Cleret-Buhot A, Zhang Y, Tremblay CL, Routy JP, Ancuta P.

Blood Adv. 2018 Nov 13;2(21):2862-2878. doi: 10.1182/bloodadvances.2018020123.

26.

Evaluation of a project to engage patients in the development of a patient-reported measure for HIV care (the I-Score Study).

Lessard D, Engler K, Toupin I; I-Score Consulting Team, Routy JP, Lebouché B.

Health Expect. 2019 Apr;22(2):209-225. doi: 10.1111/hex.12845. Epub 2018 Oct 29.

27.

Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.

Chen J, Zhang R, Shen Y, Liu L, Qi T, Wang Z, Mehraj V, Routy JP, Lu H.

HIV Med. 2019 Jan;20(1):69-73. doi: 10.1111/hiv.12679. Epub 2018 Oct 12.

PMID:
30311440
28.

Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials.

Mbuagbaw L, Slogrove AL, Sas J, Lengwe Kunda J, Morfaw F, Mukonzo JK, Cao W, Ngomba-Kadima G, Zunza M, Ongolo-Zogo P, Nana PN, Cockcroft A, Andersson N, Sewankambo N, Cotton MF, Li T, Young T, Singer J, Routy JP, Ross CJ, Thin K, Thabane L, Anis AH.

HIV AIDS (Auckl). 2018 Aug 16;10:151-155. doi: 10.2147/HIV.S150107. eCollection 2018.

29.

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

Oliveira M, Ibanescu RI, Anstett K, Mésplède T, Routy JP, Robbins MA, Brenner BG; Montreal Primary HIV (PHI) Cohort Study Group.

Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3.

30.

Plasma Indoleamine 2,3-Dioxygenase Activity Is Associated With the Size of the Human Immunodeficiency Virus Reservoir in Patients Receiving Antiretroviral Therapy.

Chen J, Xun J, Yang J, Ji Y, Liu L, Qi T, Wang Z, Zhang R, Shen Y, Ponte R, Mehraj V, Routy JP, Lu H.

Clin Infect Dis. 2019 Apr 8;68(8):1274-1281. doi: 10.1093/cid/ciy676.

31.

HIV persistence in mucosal CD4+ T cells within the lungs of adults receiving long-term suppressive antiretroviral therapy.

Costiniuk CT, Salahuddin S, Farnos O, Olivenstein R, Pagliuzza A, Orlova M, Schurr E, De Castro C, Bourbeau J, Routy JP, Ancuta P, Chomont N, Jenabian MA.

AIDS. 2018 Oct 23;32(16):2279-2289. doi: 10.1097/QAD.0000000000001962.

32.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

PMID:
30085241
33.

Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health.

Psomas C, Kinloch S, Sabin C, Soriano V, Solas C, Orkin C, Bernardino J, Curran A, Routy JP, Enel P, Philibert P, Lafeuillade A.

J Virus Erad. 2018 Jul 1;4(3):196-207.

34.

Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients.

Lu W, Feng Y, Jing F, Han Y, Lyu N, Liu F, Li J, Song X, Xie J, Qiu Z, Zhu T, Routy B, Routy JP, Li T, Zhu B.

Front Microbiol. 2018 Jul 2;9:1451. doi: 10.3389/fmicb.2018.01451. eCollection 2018.

35.

Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells.

Porichis F, Hart MG, Massa A, Everett HL, Morou A, Richard J, Brassard N, Veillette M, Hassan M, Ly NL, Routy JP, Freeman GJ, Dubé M, Finzi A, Kaufmann DE.

J Immunol. 2018 Aug 1;201(3):971-981. doi: 10.4049/jimmunol.1701551. Epub 2018 Jun 22.

36.

Use of (1→3)-β-d-glucan for diagnosis and management of invasive mycoses in HIV-infected patients.

Farhour Z, Mehraj V, Chen J, Ramendra R, Lu H, Routy JP.

Mycoses. 2018 Oct;61(10):718-722. doi: 10.1111/myc.12797. Epub 2018 Jul 5. Review.

37.

Anti-Gag antibodies gag HIV infection and slow disease progression.

Ahmad A, Mehraj V, Jenabian MA, Routy JP, Tremblay C.

AIDS. 2018 Jun 19;32(10):1373-1375. doi: 10.1097/QAD.0000000000001852. No abstract available.

PMID:
29851665
38.

Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study.

Guo F, Cheng X, Hsieh E, Du X, Fu Q, Peng W, Li Y, Song X, Routy JP, Li T.

HIV Med. 2018 May 15. doi: 10.1111/hiv.12607. [Epub ahead of print]

PMID:
29761920
39.

Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report.

Costiniuk CT, Karamchandani J, Bessissow A, Routy JP, Szabo J, Frenette C.

BMC Infect Dis. 2018 May 8;18(1):210. doi: 10.1186/s12879-018-3128-3.

40.

Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA.

Psomas CK, Lafeuillade A, Margolis D, Salzwedel K, Stevenson M, Chomont N, Poli G, Routy JP.

J Virus Erad. 2018 Apr 1;4(2):132-142.

41.

HIV induces production of IL-18 from intestinal epithelial cells that increases intestinal permeability and microbial translocation.

Allam O, Samarani S, Mehraj V, Jenabian MA, Tremblay C, Routy JP, Amre D, Ahmad A.

PLoS One. 2018 Mar 30;13(3):e0194185. doi: 10.1371/journal.pone.0194185. eCollection 2018.

42.

Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study.

Costiniuk CT, Mehraj V, Routy JP, de Castro C, Wasef N, Jenabian MA, Salahuddin S, Lebouché B, Cox J, Szabo J, Klein M, Lands L, Shapiro AJ.

AIDS Res Treat. 2018 Jan 9;2018:7645125. doi: 10.1155/2018/7645125. eCollection 2018.

43.

The Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis.

Wacleche VS, Tremblay CL, Routy JP, Ancuta P.

Viruses. 2018 Feb 6;10(2). pii: E65. doi: 10.3390/v10020065. Review.

44.

Socio-economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015.

Mehraj V, Cox J, Lebouché B, Costiniuk C, Cao W, Li T, Ponte R, Thomas R, Szabo J, Baril JG, Trottier B, Côté P, LeBlanc R, Bruneau J, Tremblay C, Routy JP; Montreal Primary HIV-Infection Study Group.

J Int AIDS Soc. 2018 Feb;21(2). doi: 10.1002/jia2.25034.

45.

Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.

Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sékaly RP.

PLoS Pathog. 2017 Dec 21;13(12):e1006740. doi: 10.1371/journal.ppat.1006740. eCollection 2017 Dec.

46.

A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.

Yue Y, Wang N, Han Y, Zhu T, Xie J, Qiu Z, Song X, Li Y, Routy JP, Wang J, Li T.

BMC Infect Dis. 2017 Dec 15;17(1):771. doi: 10.1186/s12879-017-2866-y.

47.

Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy.

Wang C, Edilova MI, Wagar LE, Mujib S, Singer M, Bernard NF, Croughs T, Lederman MM, Sereti I, Fischl MA, Kremmer E, Ostrowski M, Routy JP, Watts TH.

J Immunol. 2018 Jan 15;200(2):558-564. doi: 10.4049/jimmunol.1601254. Epub 2017 Dec 8.

48.

Very early antiretroviral therapy permits CD8 T cells to keep HIV reservoirs at bay.

Routy JP, Mehraj V.

Ann Transl Med. 2017 Nov;5(21):434. doi: 10.21037/atm.2017.08.38. No abstract available.

49.

Characterization of myeloid cell populations in human testes collected after sex reassignment surgery.

Ponte R, Dupuy FP, Brimo F, Mehraj V, Brassard P, Belanger M, Yurchenko E, Jenabian MA, Bernard NF, Routy JP; ORCHID study group.

J Reprod Immunol. 2018 Feb;125:16-24. doi: 10.1016/j.jri.2017.10.043. Epub 2017 Oct 14.

PMID:
29136520
50.

Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells.

Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, Brassard N, Silvestri G, Routy JP, Havenar-Daughton C, Crotty S, Kaufmann DE.

PLoS One. 2017 Oct 24;12(10):e0186998. doi: 10.1371/journal.pone.0186998. eCollection 2017.

Supplemental Content

Support Center